Drug Approval | May 03, 2025
Neuland Laboratories completes USFDA inspection at Unit 2
The FDA issued Form 483 with one observation related to building and facility management
The FDA issued Form 483 with one observation related to building and facility management
These observations are procedural in nature and none of them are related to data integrity
The Subsidiary has received one inspectional observation in Form 483
The company does not expect this development to have any material impact on the current business operations
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Alembic Pharma's Bioequivalence facility
USFDA inspection at Emcure Pharmaceuticals API facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
